Although inhibiting ATR to specifically target RS in cancer cell looks promising, other mechanisms of tolerating RS have been identified, such as overexpression of components of the fork protection complex [66] and recruitment of Y-family (translesion synthesis) DNA polymerases [67,68], which should be considered as possible resistance mechanisms. The gene discussed is ATR; the disease is cancer.